DCC Antibody

What is DCC and why is it significant in cancer research?

DCC (Deleted in Colorectal Carcinoma) is a tumor suppressor gene located on chromosome 18q, which is lost in more than 70% of colorectal carcinomas and almost 50% of late adenomas. This gene encodes an approximately 185 kDa transmembrane glycoprotein with significant homology to neural cell adhesion molecule (N-CAM). DCC is crucial in cancer research because its expression is typically found in normal colonic mucosa but is reduced or absent in the majority of colorectal tumors, suggesting its role in tumor suppression pathways . Beyond oncology, DCC also functions as a netrin receptor involved in axon guidance and neural development, making it relevant to neuroscience research as well .

How do I determine which DCC antibody is most appropriate for my specific research application?

Selection of the appropriate DCC antibody depends on several experimental factors:

• Target species: Verify the antibody's reactivity with your species of interest. Available options include antibodies reactive to human, mouse, rat, and other species .

• Application compatibility: Different antibodies are optimized for specific techniques:

  • For western blotting: Mouse anti-human DCC (0.5-2.0 μg/ml) or rabbit polyclonal antibodies

  • For immunohistochemistry: Antibodies validated for paraffin-embedded or frozen sections

  • For immunofluorescence: Specially designated IF/ICC antibodies

• Epitope recognition: Consider which domain of DCC your research requires:

  • N-terminal antibodies

  • Middle region antibodies (e.g., AA 642-670)

  • C-terminal antibodies

• Clone type: Determine whether monoclonal consistency (e.g., Clone G97-449) or polyclonal breadth of epitope recognition better serves your needs .

For most comprehensive analyses, validating your findings with antibodies recognizing different epitopes is recommended to ensure specificity.

What molecular weight species should I expect when using DCC antibody in western blot analysis?

When using DCC antibodies in western blot applications, you should typically observe protein species with molecular weights of approximately 175-190 kDa, with the calculated molecular weight being around 158 kDa. Notably, doublets within this range have been reported particularly in brain tissue samples. Additionally, several smaller immunoreactive species may also be detected, which could represent:

• Degradation products of the full-length protein

• Cross-reactive species

• Alternative DCC forms resulting from alternative splicing of DCC mRNA

• Products of in vivo processing of the DCC protein

To ensure specificity, it is advisable to include appropriate positive controls such as IMR-32 (ATCC CCL-127) cells, which are known to express DCC .

What are the optimal sample preparation conditions for DCC antibody in immunohistochemistry?

For optimal DCC detection in immunohistochemistry, follow these evidence-based protocols:

• Fixation: Use 10% neutral-buffered formalin fixation for 24-48 hours. Overfixation may mask epitopes.

• Processing: Standard paraffin embedding protocols are suitable, but excessive heat should be avoided during embedding.

• Sectioning: 4-5 μm sections are typically optimal for DCC detection.

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) is generally effective. Optimization may be required based on the specific antibody clone.

• Blocking: Use 5% normal serum from the species of the secondary antibody to reduce background.

• Antibody dilution: Start with the manufacturer's recommended dilution (typically 1:100 to 1:500) and optimize as needed. For example, mouse anti-human DCC antibodies have been successfully used in immunohistochemistry of formalin-fixed, paraffin-embedded tissue sections .

• Detection system: Both DAB-based and fluorescent detection systems are compatible with DCC antibodies.

It's worth noting that DCC expression is heterogeneous in tissues, with particularly strong expression in neural tissues and differentiated intestinal cells .

How should I optimize western blot protocols specifically for DCC detection?

Optimizing western blot protocols for DCC detection requires attention to several key parameters:

• Sample preparation:

  • Include protease inhibitors in lysis buffers to prevent degradation

  • Avoid excessive freeze-thaw cycles of protein samples

  • Consider using neural tissue or IMR-32 cells as positive controls

• Gel separation:

  • Use 6-8% SDS-PAGE gels to effectively resolve the high molecular weight DCC protein (175-190 kDa)

  • Consider gradient gels (4-15%) for simultaneous detection of potential degradation products

• Transfer conditions:

  • Extend transfer time (overnight at low voltage or 2+ hours at higher voltage)

  • Use PVDF membranes rather than nitrocellulose for better retention of high MW proteins

• Antibody concentration:

  • Optimal concentration ranges from 0.5-2.0 μg/ml for most DCC antibodies

  • Titrate to determine ideal concentration for your specific sample

• Blocking and washing:

  • 5% non-fat dry milk in TBST typically works well

  • BSA-based blockers may be preferable if phosphorylated forms are being studied

• Detection:

  • Enhanced chemiluminescence with longer exposure times may be necessary

  • Consider using signal enhancers for low abundance samples

• Interpretation:

  • Remember that DCC may appear as doublets (175-190 kDa range)

  • Smaller bands may represent alternative splicing or degradation products

What controls are essential when validating DCC antibody specificity?

Rigorous validation of DCC antibody specificity requires multiple types of controls:

• Positive tissue/cell controls:

  • Neural tissues (brain, spinal cord) express high levels of DCC

  • IMR-32 neuroblastoma cells (ATCC CCL-127) are recommended positive controls

  • Normal colonic mucosa (for colorectal cancer studies)

• Negative controls:

  • Tissue/cells known to lack DCC expression (many colorectal cancer cell lines)

  • DCC knockout models or DCC-null cell lines

  • Primary antibody omission controls

  • Isotype controls matching the primary antibody species and class

• Peptide competition assays:

  • Pre-incubation of the antibody with its specific immunizing peptide should abolish specific staining

  • Blocking peptides that bind specifically to the target antibody can validate specificity

• Orthogonal validation:

  • Comparison of results using antibodies targeting different DCC epitopes

  • Correlation with mRNA expression data (though post-translational modifications may affect correlation)

  • Comparison with genetic models (e.g., DCC knockout mice demonstrated that specific DCC antibody staining was absent in knockout tissues, confirming specificity)

• Cross-reactivity assessment:

  • Testing on tissues from multiple species to confirm expected cross-reactivity patterns

What are common issues when using DCC antibodies and how can they be resolved?

How do I address epitope masking issues when DCC antibody fails to detect protein in fixed tissues?

Epitope masking is a common challenge when detecting DCC in fixed tissues, particularly because its large extracellular domain contains numerous post-translational modifications that may be affected by fixation. To address this issue:

• Optimize antigen retrieval methods:

  • Test multiple heat-induced epitope retrieval buffers (citrate pH 6.0, EDTA pH 9.0, Tris-EDTA pH 8.0)

  • Compare microwave, pressure cooker, and water bath heating methods

  • Consider enzymatic retrieval (proteinase K, trypsin) for heavily fixed samples

• Adjust fixation protocols:

  • Limit fixation time to 24-48 hours when possible

  • Consider testing alternative fixatives (zinc-based fixatives may preserve some epitopes better)

  • For prospective studies, prepare both frozen and fixed samples

• Try different DCC antibody clones:

  • Antibodies targeting different epitopes may have varying sensitivity to fixation effects

  • Middle region (AA 642-670) antibodies may perform differently than N-terminal or C-terminal antibodies

• Signal amplification strategies:

  • Employ tyramide signal amplification systems

  • Use polymer-based detection systems for enhanced sensitivity

  • Consider biotin-free detection systems to reduce background

• Sample preparation adjustments:

  • Extend permeabilization time for better antibody penetration

  • Use detergents (0.1-0.3% Triton X-100) to improve accessibility to membrane-associated DCC

Researchers have successfully detected DCC in formalin-fixed, paraffin-embedded tissue sections using specific antibody clones with appropriate optimization of these parameters .

How can DCC antibodies be employed to study the role of DCC in axon guidance and neural development?

DCC antibodies have proven instrumental in elucidating the functions of DCC in neural development through several sophisticated approaches:

• Developmental expression mapping:

  • Immunohistochemical analyses using DCC antibodies have revealed spatiotemporal expression patterns during embryonic and postnatal development

  • This has enabled correlation of DCC expression with critical periods of axon guidance and synaptogenesis

• Subcellular localization studies:

  • High-resolution immunofluorescence with DCC antibodies has demonstrated localization to growth cones and axonal membranes

  • Colocalization studies with netrin-1 and other guidance molecules reveal interaction domains

• Functional blocking experiments:

  • Function-blocking DCC antibodies that target the netrin-binding domain can disrupt axon guidance in ex vivo slice cultures

  • These experiments have demonstrated the necessity of DCC-netrin signaling for proper commissural axon crossing

• Investigation of DCC in astroglial development:

  • Research using DCC antibodies has revealed previously unknown functions in astroglial development essential for telencephalic morphogenesis and corpus callosum formation

  • Knockout mice studies confirmed antibody specificity in identifying DCC within both commissural axons and midline zipper glia (MZG) cells

• Receptor complex formation analysis:

  • Co-immunoprecipitation using DCC antibodies helps identify binding partners in the netrin signaling pathway

  • This approach has revealed how DCC associates with other receptors like UNC5 to mediate attraction versus repulsion

• Live imaging applications:

  • Modified non-blocking DCC antibodies conjugated to fluorophores enable visualization of receptor dynamics during axon pathfinding in living tissue

For researchers investigating DCC in neural development, it's particularly valuable to note that DCC knockout mice studies have validated antibody specificity, showing absence of staining in knockout tissues while confirming DCC expression in commissural axons under normal conditions .

What methodological approaches are recommended for studying the relationship between DCC expression and colorectal cancer progression?

To investigate the relationship between DCC expression and colorectal cancer progression, several methodological approaches using DCC antibodies are recommended:

• Tissue microarray (TMA) analysis:

  • Create TMAs from patient samples representing different stages of colorectal cancer progression

  • Use optimized immunohistochemistry protocols with validated DCC antibodies

  • Implement digital pathology quantification for objective scoring of DCC expression

• Correlation with genomic alterations:

  • Combine DCC immunohistochemistry with analysis of chromosome 18q status (FISH, SNP arrays)

  • Correlate protein expression with allelic loss patterns

  • Remember that chromosome 18 is lost in >70% of carcinomas and ~50% of late adenomas

• Multi-marker progression panels:

  • Develop multiplex immunohistochemistry panels including DCC and other colorectal progression markers

  • Include markers for microsatellite instability, KRAS/BRAF mutations, and other 18q genes

• Longitudinal expression studies:

  • Analyze matched samples from the same patients at different disease stages

  • Compare normal mucosa, adenoma, carcinoma, and metastatic tissue

  • DCC mRNA is expressed in normal colonic mucosa but reduced/absent in most colorectal tumors

• Functional validation in model systems:

  • Use DCC antibodies to confirm expression changes in patient-derived xenografts or organoids

  • Correlate with invasive potential and metastatic behavior

  • Employ inducible DCC expression systems to study phenotypic changes

• Prognostic significance assessment:

  • Correlate DCC immunohistochemistry scores with patient outcomes using Kaplan-Meier analyses

  • Control for treatment modalities and other prognostic factors

  • Consider both intensity and pattern of DCC expression

• Mechanistic studies of DCC loss:

  • Use antibodies to detect truncated forms or degradation products that might indicate specific inactivation mechanisms

  • Western blot analyses should account for potential degradation products, cross-reactive species, or alternatively spliced forms of DCC

How can I use DCC antibodies to investigate the dual role of DCC in both tumor suppression and axon guidance?

Investigating the dual role of DCC requires sophisticated experimental approaches that bridge oncology and neuroscience:

• Domain-specific functional analysis:

  • Employ antibodies targeting different DCC domains (extracellular vs. intracellular) to distinguish between netrin-binding regions and potential tumor suppressor domains

  • Compare antibodies recognizing the N-CAM homology domain (42% sequence homology to cell adhesion proteins) versus intracellular signaling regions

• Signaling pathway dissection:

  • Use phospho-specific DCC antibodies (if available) to study activation of downstream pathways

  • Compare netrin-1-induced signaling cascades with those activated in tumor suppression contexts

  • Perform immunoprecipitation with DCC antibodies followed by phosphoproteomic analysis

• Conditional expression systems:

  • Establish model systems with inducible DCC expression or domain-specific mutations

  • Use DCC antibodies to confirm expression and localization in these systems

  • Monitor both tumor-related phenotypes and neurodevelopmental outcomes

• Tissue context comparison:

  • Apply identical DCC antibody protocols to neural tissues and epithelial/tumor tissues

  • Analyze differences in DCC interactome between these tissue contexts

  • Look for cell-type specific post-translational modifications or binding partners

• Coordinate analysis with netrin-1:

  • Perform co-staining of DCC and netrin-1 in both neural and tumor tissues

  • Investigate the dependence relationship (netrin-1 as a ligand in neural guidance vs. potential autocrine signaling in tumors)

  • Compare with Dcc and Ntn1 mRNA expression patterns

• Structural biology approaches:

  • Use conformation-specific antibodies (if available) to detect different DCC conformational states

  • Investigate whether tumor suppressor functions involve different structural states than axon guidance functions

• Single-cell analysis:

  • Apply DCC antibodies in single-cell protein analysis platforms

  • Compare DCC expression heterogeneity between neural precursors and tumor cell populations

What are the latest developments in using DCC antibodies for novel imaging techniques in neurodevelopmental research?

Recent technological advances have expanded the utility of DCC antibodies in neurodevelopmental research:

• Super-resolution microscopy applications:

  • STORM/PALM microscopy with DCC antibodies now enables visualization of receptor nanoclusters at growth cones

  • Stimulated emission depletion (STED) microscopy allows for tracking of DCC receptor dynamics during axon guidance with nanometer precision

  • These approaches have revealed previously undetectable patterns of DCC distribution during commissural axon development

• Intravital imaging with minimally disruptive antibodies:

  • Development of smaller antibody fragments (Fabs, nanobodies) against DCC enables live imaging with reduced interference

  • Two-photon microscopy with these reagents allows visualization of DCC dynamics in intact developing brain tissue

  • Correlation of DCC distribution with real-time axon guidance decisions

• Expansion microscopy compatibility:

  • Protocols have been optimized for using DCC antibodies in expanded neural tissues

  • This allows visualization of DCC subcellular localization with improved resolution in complex 3D structures

  • Particularly valuable for studying DCC in densely packed commissural regions

• Antibody-based proximity labeling:

  • DCC antibodies conjugated to enzymes like APEX2 or BioID allow for proximity-based labeling

  • This enables identification of transient DCC interaction partners during specific developmental stages

  • Has revealed previously unknown components of the DCC interactome in commissural axons

• Multiplexed imaging platforms:

  • Cyclic immunofluorescence and mass cytometry using DCC antibodies

  • Allows simultaneous visualization of DCC with dozens of other neural markers

  • Reveals complex cellular relationships, particularly at choice points where multiple guidance systems interact

• Correlative light and electron microscopy (CLEM):

  • DCC antibodies optimized for both fluorescence and electron microscopy

  • Enables correlation between DCC localization and ultrastructural features

  • Particularly valuable for studying DCC at the growth cone membrane

Recent studies implementing these advanced imaging approaches have provided insights into DCC's role in astroglial development and corpus callosum formation, confirming antibody specificity through knockout mouse models .

How do different fixation and permeabilization methods affect DCC epitope detection and what are the optimal conditions for specific research questions?

Permeabilization Optimization:

For DCC as a transmembrane protein, permeabilization requires careful balancing:

• 0.1% Triton X-100 (5-15 minutes): Suitable for accessing intracellular domains while preserving most epitopes

• 0.1% Saponin: Gentler permeabilization that better preserves membrane structure

• Digitonin (10-50 μg/ml): Selectively permeabilizes plasma membrane, useful for distinguishing surface vs. intracellular DCC pools

Different experimental questions require specific optimization:

• For studies focusing on DCC's extracellular netrin-binding domain, milder fixation (short PFA) with minimal permeabilization

• For investigations of intracellular signaling domains, stronger permeabilization may be necessary

• For dual examination of both domains, sequential immunostaining with different fixation/permeabilization protocols may be optimal

Research has shown that detection of DCC in commissural axons and MZG cells can be optimized using appropriate fixation and antibody validation through knockout mice models .

How should researchers interpret contradictory results between DCC antibody detection and mRNA expression data?

Contradictions between DCC protein detection using antibodies and mRNA expression data are not uncommon and require careful interpretation:

• Post-transcriptional regulation mechanisms:

  • DCC may be subject to microRNA regulation affecting translation efficiency

  • RNA stability factors may lead to discrepancies between mRNA levels and protein abundance

  • Investigation of these mechanisms may require specialized assays beyond standard antibody detection

• Post-translational modifications and processing:

  • DCC undergoes complex post-translational processing that may affect antibody recognition

  • Proteolytic cleavage events can generate fragments not detectable by all antibodies

  • Western blot analyses often reveal multiple bands representing degradation products, alternatively spliced forms, or processed variants

• Epitope-specific detection limitations:

  • Different antibodies targeting various DCC domains may give contradictory results

  • Some epitopes may be masked in certain cellular contexts or fixation conditions

  • Important to use multiple antibodies targeting different regions for confirmation

• Technical considerations for reconciliation:

  • Compare sensitivity thresholds of RT-PCR vs. immunodetection methods

  • Consider subcellular localization and potential concentration effects

  • Implement absolute quantification methods for both protein and mRNA

• Biological significance of discrepancies:

  • Temporal delays between transcription and translation

  • Cell-type specific post-transcriptional regulation

  • Protein stability differences across tissues

• Case study reference:

  • In studies of telencephalic morphogenesis, researchers noted that specific staining for both Dcc and Ntn1 mRNA was not observed in certain regions (IHF including leptomeninges) at any stage analyzed, despite protein detection in these areas

  • This illustrates the importance of considering protein trafficking and localization distinct from sites of mRNA expression

When encountering such discrepancies, researchers should implement complementary approaches including multiple antibodies, in situ hybridization with different probes, and genetic validation models.

What statistical approaches are recommended for quantifying and comparing DCC expression levels in immunohistochemistry studies?

Robust statistical analysis of DCC immunohistochemistry requires systematic approaches:

• Scoring systems optimization:

  • Implement standardized scoring systems combining intensity and percentage positivity

  • H-score method (0-300 scale): multiply intensity (0-3) by percentage of positive cells (0-100%)

  • Allred scoring system (0-8 scale): combines proportion score (0-5) and intensity score (0-3)

  • Digital pathology quantification using color deconvolution and automated intensity measurement

• Appropriate statistical tests:

  • For comparing DCC expression between two groups: t-test (parametric) or Mann-Whitney U test (non-parametric)

  • For multiple group comparisons: ANOVA with post-hoc tests (parametric) or Kruskal-Wallis (non-parametric)

  • For correlating DCC levels with continuous variables: Pearson's or Spearman's correlation coefficients

  • For survival analyses: Kaplan-Meier curves with log-rank tests and Cox proportional hazards models

• Controlling for confounding variables:

  • Implement multivariate analyses to account for patient demographics, tumor stage, treatment history

  • Consider mixed effects models for studies with repeated measures or matched samples

  • Use propensity score matching for observational studies with potential selection bias

• Addressing heterogeneity:

  • Quantify intratumoral heterogeneity using spatial statistics

  • Implement hot-spot analysis for regions of highest DCC expression

  • Consider tissue microarray spot replication and averaging strategies

• Validation and reproducibility:

  • Inter-observer and intra-observer variability assessment using kappa statistics

  • Bootstrapping or cross-validation approaches for predictive models

  • Sample size calculations based on preliminary data to ensure adequate statistical power

• Integration with molecular data:

  • Correlation of DCC protein expression with chromosome 18q status

  • Implementation of integrative clustering approaches combining protein, genomic and clinical data

  • Machine learning algorithms for pattern recognition in complex datasets

• Reporting standards:

  • Clear documentation of antibody validation steps

  • Transparent reporting of scoring methods, cutoff determination, and statistical approaches

  • Sharing of raw data and analysis code when possible

These approaches enable robust quantitative comparisons while accounting for the technical and biological variability inherent in DCC immunohistochemistry studies.